leisure time -WSS

leisure time

author：hotspot 2025-09-06 03:54:23 - browse：47299

Portrait of Don Davis -- health policy coverage from STAT — U.S. Representative Don Davis (D-N.C.) Wikimedia Commons

WASHINGTON — Two Republican lawmakers who introduced legislation to water down the Inflation Reduction Act’s Medicare drug price negotiation program managed to find themselves a Democratic co-sponsor — even though every single Democrat in Congress in 2022 voted for the legislation.

They found their perfect candidate in Rep. Don Davis, a Democrat representing a North Carolina district that includes parts of the state’s Research Triangle. He came to Washington in 2023, so didn’t vote on the original law. He received donations in 2023 from the political action committees for Gilead, Astellas, Genentech, Bayer, Pfizer, Novo Nordisk, GSK, Bristol Myers Squibb, BIO, Amgen, Boehringer Ingelheim, Merck, AbbVie, and Eli Lilly.

“We must support the development of critical, life-sustaining medical treatments and cures,” Davis said in a written statement, and a spokesperson declined to elaborate. He is joined on the bill by Rep. Greg Murphy (R-N.C.) and Brett Guthrie (R-Ky.), the Energy and Commerce health subcommittee chairman.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： UCB departs biotech trade group BIO

focus

WSS

New clues to why women have higher risk of autoimmune disorders

Wegovy leads to weight loss. Can it treat depression, too?

Boston competes with Raleigh

Goldman Sachs launches $650M fund for life science investments

The FDA must approve intranasal treatments for anaphylaxis

How generative AI ratchets up security threats for health systems

hotspot

leisure time

knowledge

Peter Hotez and the public health issue of online harassment

Ahead of JPM, here's who's profiting most in health care

Drug repurposing or repositioning? The language matters

Why you shouldn’t ask, “What country has the best health care?”

Hepatitis C has a cure — but many Americans still lack access to it

Boston competes with Raleigh

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

The FDA must approve intranasal treatments for anaphylaxis

The cancer drug shortage isn’t new — and neither are the solutions

The FDA must approve intranasal treatments for anaphylaxis

focus

How generative AI ratchets up security threats for health systems

3 trends to watch in health tech's hiring outlook for 2024

U.K. sequencing study surfaces new findings about tumor DNA

White House finalizes ITC's import ban of latest Apple Watches

The FDA must approve intranasal treatments for anaphylaxis

The biotech scorecard for Q1: 17 stock

hotspot

hotspot

focus

explore